Three-Dimensional Screen Printing Technology Enables Sequential Release of Carbidopa and Levodopa – A New Approach Improving Levodopa Delivery for Treating Parkinson’s Disease
Levodopa is the most effective treatment for Parkinson’s disease, but conventional short-acting formulations often cause motor complications due to fluctuating dopamine levels.
This article highlights Adare's 3D screen printing partner, Laxxon Medical, and its printing strategy to produce tablets with sequential carbidopa and levodopa release for more stable dopaminergic stimulation.
Click "download" or "view" below to access this resource.
